계명대학교 의학도서관 Repository

Clinical Outcomes of ABO-Incompatible Kidney Transplant with Rituximab and Double-Filtration Plasmapheresis

Metadata Downloads
Author(s)
Seungyeup HanEunah HwangSungbae ParkUijun ParkHyoungtae KimWonhyun Cho
Keimyung Author(s)
Han, Seung YeupHwang, Eun AhPark, Sung BaePark, Ui JunKim, Hyoung TaeCho, Won Hyun
Department
Dept. of Internal Medicine (내과학)
Dept. of Surgery (외과학)
Kidney Institute (신장연구소)
Journal Title
Experimental and Clinical Transplantation
Issued Date
2014
Volume
12
Issue
5
Abstract
Objectives: The best treatment for end-stage renal
disease is kidney transplant, but the shortage of
donor organs has caused long waiting times for an
appropriate organ allograft. The use of ABOincompatible
kidney transplant can be a valuable
option to expand the donor pool. The purpose
of the present study was to evaluate 13 patients
who had successful ABO-incompatible kidney
transplant with double-filtration plasmapheresis and
rituximab.
Materials and Methods: From January 2011 to
August 2012, there were 13 patients who had ABOincompatible
kidney transplant. Antibody titers
were monitored during preconditioning and after
transplant. Preconditioning protocol included
rituximab, mycophenolate mofetil, tacrolimus,
corticosteroids, double-filtration plasmapheresis,
and intravenous immunoglobulin.
Results: There were no episodes of acute T-cell or
antibody-mediated rejection. There were no surgical
complications except postoperative bleeding in 1
patient. Mean serum creatinine at 2 weeks after
transplant was 71 ± 18 μmol/L (0.8 ± 0.2 mg/dL). At
mean follow-up 267 days (range, 1-19 mo), there
was no graft loss or patient death.
Conclusions: The ABO-incompatible kidney transplants
were successful after the preconditioning
protocol that included double-filtration plasmapheresis
and rituximab. The use of ABO-incompatible
kidney transplant may increase the availability of
kidney transplant and avoid or shorten dialysis.
Future multicenter studies are justified to develop a
standardized preconditioning protocol.
Key words: End-stage renal disease, Preconditioning,
Rejection, Treatment
Keimyung Author(s)(Kor)
한승엽
황은아
박성배
박의준
김형태
조원현
Publisher
School of Medicine
Citation
Seungyeup Han et al. (2014). Clinical Outcomes of ABO-Incompatible Kidney
Transplant with Rituximab and Double-Filtration
Plasmapheresis. Experimental and Clinical Transplantation, 12(5), 401–404. doi: 10.6002/ect.2014.0075
Type
Article
ISSN
1304-0855
Source
http://www.ectrx.org/forms/ectrxcontentshow.php?year=2014&volume=12&issue=5&supplement=0&makale_no=0&spage_number=401&content_type=FULL%20TEXT
DOI
10.6002/ect.2014.0075
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35697
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
1. School of Medicine (의과대학) > Dept. of Surgery (외과학)
3. Research Institutues (연구소) > Kidney Institute (신장연구소)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.